Healix

Outcomes Research

Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.

Our data warehouse is the largest in the outpatient infusion industry. Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence.

Additionally, the strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.

Here is an example of one of our class-leading studies enabled by our data:

infection-incidence

Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)

Lucinda J. Van Anglen, PharmD
Thomas C. Hardin, PharmD,
Claudia P. Schroeder, PharmD, PhD
Open Forum Infect Dis (Fall 2018) 5 (suppl1): doi:10.1093/ofid/ofy210.2020

All Related Studies

Cost Savings & Lower Resource Utilization

Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings

Robin H. Dretler, MD, FIDSA
Quyen Luu, MD
Richard C. Prokesch, MD, FACP, FIDSA
Andrew H. Krinsky, MD
H. Barry Baker, MD, FACP
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Read More

A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC)

Barry Statner, MD, CM FRCPC, FIDSA
Fernando S. Alvarado, MD, MPH, TM
Brian Metzger, MD, MPH
Richard M. Mandel, MD, FIDSA
Jorge R. Bernett, MD
H. Barry Baker, MD, FACP
Alfred E. Bacon III, MD
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2015) 2 (suppl 1): doi:10.1093/ofid/ofv133.1017

Read More

Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs. Traditional Home Health Care (HHC)

Richard C. Prokesch, MD, FACP, FIDSA
John S. Adams, MD, FIDSA
Ramesh V. Nathan, MD
Claudia P. Schroeder, PharmD
Lucinda J. Van Anglen, PharmD
K. Dale Hooker, PharmD

Read More

Cost Savings Utilizing Outpatient Parenteral Antimicrobial Therapy (OPAT) for Treatment of Complicated Skin and Skin Structure Infections (cSSSI) in Physician Operated Infusion Centers (POICs) without Hospitalization

Lucinda J. Van Anglen, PharmD
Michael P. Dailey, MD
Andrew H. Krinsky, MD
John S. Adams, MD

Read More
All Related Studies

Clinical Outcomes

Outpatient Treatment of Osteomyelitis with Telavancin

Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD
Robin H. Dretler, MD
John S. Adams, MD, FIDSA, FSHEA
Richard C. Prokesch, MD, FACP, FIDSA
Quyen Luu, MD
Andrew H. Krinsky, MD

(doi: 10.1016/j.ijantimicag.2017.01.034). It appears in The International Journal of Antimicrobial Agents, Volume 50, Issue 1, 93 – 96 (2017), published by Elsevier

Read More

Outpatient Treatment of Infective Endocarditis at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes

Brian S. Metzger, MD, MPH
Richard M. Mandel, MD, FIDSA
Jorge R. Bernett, MD
Barry Statner, MD, FRCPC, FIDSA
John S. Adams, MD, FIDSA, FSHEA
Alfred E. Bacon, III, MD
Kimberly Couch, PharmD, MA, FIDSA, FASHP
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2016) 3 (suppl 1): doi:10.1093/ofid/ofw172.823

Read More

Real Word Evaluation of Prolonged Clinical Response with Vedolizumab in Crohn's Disease and Ulcerative Colitis patients Treated in a Private Practice Setting

Timothy E. Ritter, MD
Christopher Fourment, MD
Lucinda J. Van Anglen, PharmD
Tracy C. Okoro, PharmD
Thomas C. Hardin, PharmD

CCFA 2018 #P189

Read More

Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) Treated in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis

Brian S. Metzger, MD, MPH
John S. Adams, MD, FIDSA, FSHEA
Jorge R. Bernett, MD
Richard M. Mandel, MD, FIDSA
Richard C. Prokesch, MD, FACP, FIDSA
Carson T. Lo, MD
Thomas C. Hardin, PharmD
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.324

Read More
All Related Studies

Special Populations

Real-World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease

Annette E. Whitney, MD
Harry E. Sarles, Jr., MD, FACG
Claudia P. Schroeder, PharmD, PhD
Tracy C. Okoro, PharmD
Lucinda J. Van Anglen, PharmD

Read More

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population

Lucinda J. Van Anglen, PharmD
Richard M. Mandel, MD, FIDSA
Ramesh V. Nathan, MD, FIDSA
Andrew H. Krinsky, MD
Quyen Luu, MD
Alfred E. Bacon, III, MD
H. Barry Baker, MD, FACP
Claudia P. Schroeder, PharmD, PhD
Kimberly A. Couch, PharmD

Read More
All Related Studies

Persistence

Tolerability and Persistence with Subcutaneous Immunoglobulin Provided Through Physician Clinics for the Treatment of Primary Immunodeficiencies

Richard F. Herrscher, MD, FACAAI
Tidence L. Prince, MD
Lucinda J. Van Anglen, PharmD
Claudia P. Schroeder, PharmD, PhD

Read More
All Related Studies

New Therapies and Programs

 

Effective Antimicrobial Stewardship for Outpatient Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Diseases Physician Infusion Centers

Ramesh V. Nathan, MD
Richard L. Hengel, MD
Andrew H. Krinsky, MD
Thomas K. Sleweon, MD
Alfred E. Bacon III, MD
Dale Hooker, PharmD
Claudia P. Schroeder, PharmD, PhD
Kimberly A. Couch, PharmD, MA
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093.ofid/ofy210.1510

Read More

Evaluation of Bezlotoxumab in Prevention of Recurrent C. Difficile Infection: A multicenter Single-Arm Study in Office Infusion Centers

Richard L. Hengel, MD
Timothy E. Ritter, MD
Ramesh V. Nathan, MD, FIDSA
Lucinda J. Van Anglen, PharmD
Stephen W. Marcella
Kevin W. Garey, Pharm.D., M.S., FASHP

Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.510

Read More

Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers

Quyen Luu, MD
Barry Statner, MD, FRCPC, FIDSA
Robin H. Dretler, MD, FIDSA
H. Barry Baker, MD, FACP
Brian S. Metzger, MD, MPH
Thomas C. Hardin, PharmD
Claudia P. Schroeder, PharmD, PhD
Lucinda J. Van Anglen, PharmD

Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.2033

Read More

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound